Helix Acqsn II SEC Filings

BridgeBio Oncology Therapeutics, Inc. (BBOT) initial Form 3 filed for Pedro Beltran, the company's Chief Scientific Officer, discloses two stock option grants totaling 469,849 underlying shares. One option covers 443,298 shares exercisable starting 07/22/2034 at $4.17 per share; the second covers 26,551 shares exercisable starting 04/02/2035 at $7.88 per share. Vesting occurs in 1/48th monthly installments from May 1, 2024 and April 4, 2025 respectively. The filing date of the event is 08/11/2025.

Amendment No. 2 to a Schedule 13D reports that the Reporting Persons — including Helix Holdings II LLC (Sponsor), several Cormorant funds and Bihua Chen — hold an aggregate of 17,878,594 shares of BridgeBio Oncology Therapeutics, Inc. Common Stock, representing 22.6% of the outstanding shares based on 79,196,710 shares outstanding. The filing documents the Domestication and Merger that converted Helix securities into the Issuer's Common Stock and notes Sponsor forfeitures totaling 460,814 shares across two forfeiture events tied to the transaction.

The Reporting Persons participated in the PIPE closing and purchased 6,998,031 shares at $10.7173 per share. They entered into a Lock-Up Agreement that restricts transfers of their pre-closing shares for one year after the later of the Form 10 filing or the closing date, but the lock-up excludes shares purchased in the PIPE. The filing also references registration rights and several transaction agreements and discloses that Ms. Chen serves on the Issuer's board and has voting and investment discretion over the Cormorant funds and the Sponsor.

Bihua Chen reported multiple ownership changes in BridgeBio Oncology Therapeutics, Inc. ("BBOT") tied to the closing of Helix Acquisition Corp. II's business combination and related subscription activity. On 08/11/2025, several Cormorant-managed funds purchased shares from the issuer: Fund III bought 760,496 shares, Fund V bought 639,110 shares, and Master Fund bought 5,598,425 shares, each at a purchase price of $10.7173 per share. These purchases were made under a subscription agreement with Helix.

Separately, the Sponsor forfeited shares for no consideration prior to closing: the forfeiture of 307,874 Class B ordinary shares and 152,940 shares of Common Stock is disclosed. The filing also explains that Helix's Class B shares converted into Class A shares and, following domestication, Class A shares converted one-for-one into the issuer's Common Stock. Ms. Chen is disclosed as manager with voting and investment discretion for the Sponsor and the Cormorant funds, while disclaiming beneficial ownership beyond any pecuniary interest.

BridgeBio Oncology Therapeutics, Inc. completed its business combination on August 11, 2025, when Helix Acquisition Corp. II domesticated to Delaware, merged with TheRas, Inc. (d/b/a BBOT) and changed its name to BridgeBio Oncology Therapeutics, Inc. At closing PubCo listed on Nasdaq under the symbol BBOT. PubCo received gross proceeds of approximately $381.8 million before transaction expenses, including $120.9 million from Helix's trust account and $260.9 million from a concurrent PIPE of 24,343,711 shares at $10.7173 per share. Helix Class A shareholders redeemed 7,119,750 shares for an aggregate of approximately $76.3 million.

Pro forma shares outstanding include 79,196,710 PubCo Common Stock. Approximately 61.1 million shares (about 77.2%) are subject to registration rights. The registry of new governance and compensation arrangements includes appointments of Eli Wallace as CEO, Uneek Mehra as CFO, Pedro Beltran as CSO and Yong Ben as Chief Medical and Development Officer, executive base salaries (e.g., Wallace $550,800) and approved equity plans (2025 Plan initial reserve 5,373,641 shares; ESPP initial reserve 895,607 shares). The company dismissed WithumSmith+Brown and engaged Deloitte; Withum's report included an explanatory going concern paragraph for Helix as of December 31, 2024.

Albert A. Holman III reported a non‑cash conversion of equity in connection with Helix Acquisition Corp. II's business combination and domestication that resulted in holdings in BridgeBio Oncology Therapeutics, Inc. [BBOT]. On 08/11/2025 Mr. Holman's 30,000 Class B ordinary shares were converted one‑for‑one into Helix Class A ordinary shares and then into 30,000 shares of the issuer's common stock at a price of $0 per share, leaving him with 30,000 shares beneficially owned in a direct ownership form. The filing also notes he resigned as a director of Helix effective the same date, immediately prior to the domestication.

This Form 4 documents a structural conversion tied to the closing of the business combination and domestication rather than an open‑market purchase or sale.

Mark C. McKenna filed a Form 4 reporting ownership changes tied to the business combination and domestication of Helix Acquisition Corp. II into the issuer, which is identified here as BridgeBio Oncology Therapeutics, Inc. [BBOT]. On 08/11/2025 McKenna's 30,000 Helix shares were converted through a one-for-one exchange of Class B ordinary shares into Class A ordinary shares and then into the issuer's common stock, resulting in 30,000 common shares beneficially owned, held directly. The filing shows the conversion occurred at $0 consideration as part of the corporate reorganization. The filer also resigned as a director of Helix effective the same date immediately prior to the domestication.